Patrice Grand. Picture: Merck

Mundipharma today announced the appointment of Patrice Grand to the position of European Director of Corporate Communications.

© 123rf.com/sangoiri

Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.

Plastics production from 1950 to 2017. © nova-institute

The market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute. 

Healthy (left) and type 1 diabetes (right) islet of Langerhans in the pancreas. ©  123rf.com/designua

Swiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas

Dr_Nathwani_350.jpg

Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer.

Afyren's current preindustrial production plant.© Afyren

French industrial biotech company Afyren announced a capital increase of €21m in a financing round led by  Sofinnova Partners and Valquest Partners to scale up its biobased organic acid production to industrial scale.

Picture: WWF

After a quick start out the gates in 2012, the European Commission proceeded to carry out a lengthy review of its bioeconomy strategy – slamming the brakes on investor interest in EU bio­techs developing solutions for the move to a low-carbon, zero-waste economy. Following several reports that suggested the bloc will miss internationally agreed sustainability targets, the EC now wants to speed up the switch to biobased production. Industry stakeholders presented a huge range of promising technologies at the EFIB, but are still awaiting the go-ahead.

© Biotech Campus Delft
Biotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.  
© 123rf.com/decade3d

Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.

Suggested mode of action of OSE-127: Blocking of an epitope overlapping the
IL-7 binding domain and the receptor heterodimerization region prevents activation of JAK/STAT signaling as well as PI3K and Erk
signaling, which blocks inflammation by neutralisation of IFN-gamma producing antigen-specific memory T cells © Nature Communicationsvolume 9, Article number: 4483 (2018)

Ose Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.